Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 4 of 4
Full-Text Articles in Entire DC Network
In Vivo Evaluation Of (-)-Zampanolide Demonstrates Potent And Persistent Antitumor Efficacy When Targeted To The Tumor Site., Leila Takahashi-Ruiz, Joseph D Morris, Phillip Crews, Tyler A Johnson, April L Risinger
In Vivo Evaluation Of (-)-Zampanolide Demonstrates Potent And Persistent Antitumor Efficacy When Targeted To The Tumor Site., Leila Takahashi-Ruiz, Joseph D Morris, Phillip Crews, Tyler A Johnson, April L Risinger
Natural Sciences and Mathematics | Faculty Scholarship
Microtubule-stabilizing agents (MSAs) are a class of compounds used in the treatment of triple-negative breast cancer (TNBC), a subtype of breast cancer where chemotherapy remains the standard-of-care for patients. Taxanes like paclitaxel and docetaxel have demonstrated efficacy against TNBC in the clinic, however new classes of MSAs need to be identified due to the rise of taxane resistance in patients. (-)-Zampanolide is a covalent microtubule stabilizer that can circumvent taxane resistance in vitro but has not been evaluated for in vivo antitumor efficacy. Here, we determine that (-)-zampanolide has similar potency and efficacy to paclitaxel in TNBC cell lines, but …
A Novel Rapamycin Analog Is Highly Selective For Mtorc1 In Vivo., Katherine H. Schreiber, Sebastian I. Arriola Apelo, Deyang Yu, Jacqueline A Brinkman, Michael C Velarde, Faizan A Syed, Chen-Yu Liao, Emma L. Baar, Kathryn A. Carbajal, Dawn S. Sherman, Denise Ortiz, Regina Brunauer, Shany E. Yang, Stelios T Tzannis, Brian K Kennedy, Dudley W Lamming
A Novel Rapamycin Analog Is Highly Selective For Mtorc1 In Vivo., Katherine H. Schreiber, Sebastian I. Arriola Apelo, Deyang Yu, Jacqueline A Brinkman, Michael C Velarde, Faizan A Syed, Chen-Yu Liao, Emma L. Baar, Kathryn A. Carbajal, Dawn S. Sherman, Denise Ortiz, Regina Brunauer, Shany E. Yang, Stelios T Tzannis, Brian K Kennedy, Dudley W Lamming
Natural Sciences and Mathematics | Student Professional Publications
Rapamycin, an inhibitor of mechanistic Target Of Rapamycin Complex 1 (mTORC1), extends lifespan and shows strong potential for the treatment of age-related diseases. However, rapamycin exerts metabolic and immunological side effects mediated by off-target inhibition of a second mTOR-containing complex, mTOR complex 2. Here, we report the identification of DL001, a FKBP12-dependent rapamycin analog 40x more selective for mTORC1 than rapamycin. DL001 inhibits mTORC1 in cell culture lines and in vivo in C57BL/6J mice, in which DL001 inhibits mTORC1 signaling without impairing glucose homeostasis and with substantially reduced or no side effects on lipid metabolism and the immune system. In …
Rpl24: A Potential Therapeutic Target Whose Depletion Or Acetylation Inhibits Polysome Assembly And Cancer Cell Growth., Kathleen A. Wilson-Edell, Amanuel Kehasse, Gary K. Scott, Christina Yau, Daniel E. Rothschild, Birgit Schilling, Bianca S Gabriel, Mariya A. Yevtushenko, Ingrid M. Hanson, Jason M. Held, Bradford W. Gibson, Christopher C. Benz
Rpl24: A Potential Therapeutic Target Whose Depletion Or Acetylation Inhibits Polysome Assembly And Cancer Cell Growth., Kathleen A. Wilson-Edell, Amanuel Kehasse, Gary K. Scott, Christina Yau, Daniel E. Rothschild, Birgit Schilling, Bianca S Gabriel, Mariya A. Yevtushenko, Ingrid M. Hanson, Jason M. Held, Bradford W. Gibson, Christopher C. Benz
Natural Sciences and Mathematics | Student Professional Publications
Partial loss of large ribosomal subunit protein 24 (RPL24) function is known to protect mice against Akt or Myc-driven cancers, in part via translational inhibition of a subset of cap(eIF4E)-dependently translated mRNAs. The role of RPL24 in human malignancies is unknown. By analyzing a public dataset of matched human breast cancers and normal mammary tissue, we found that breast cancers express significantly more RPL24 than matched normal breast samples. Depletion of RPL24 in breast cancer cells by >70% reduced cell viability by 80% and decreased protein expression of the eIF4E-dependently translated proteins cyclin D1 (75%), survivin (46%) and NBS1 (30%) …
The Marine Sponge Metabolite Mycothiazole: A Novel Prototype Mitochondrial Complex I Inhibitor., J Brian Morgan, Fakhri Mahdi, Yang Liu, Veena Coothankandaswamy, Mika B. Jekabsons, Tyler A. Johnson, Koneni V. Sashidhara, Phillip Crews, Dale G. Nagle, Yu-Dong Zhou
The Marine Sponge Metabolite Mycothiazole: A Novel Prototype Mitochondrial Complex I Inhibitor., J Brian Morgan, Fakhri Mahdi, Yang Liu, Veena Coothankandaswamy, Mika B. Jekabsons, Tyler A. Johnson, Koneni V. Sashidhara, Phillip Crews, Dale G. Nagle, Yu-Dong Zhou
Natural Sciences and Mathematics | Faculty Scholarship
A natural product chemistry-based approach was applied to discover small-molecule inhibitors of hypoxia-inducible factor-1 (HIF-1). A Petrosaspongia mycofijiensis marine sponge extract yielded mycothiazole (1), a solid tumor selective compound with no known mechanism for its cell line-dependent cytotoxic activity. Compound 1 inhibited hypoxic HIF-1 signaling in tumor cells (IC(50) 1nM) that correlated with the suppression of hypoxia-stimulated tumor angiogenesis in vitro. However, 1 exhibited pronounced neurotoxicity in vitro. Mechanistic studies revealed that 1 selectively suppresses mitochondrial respiration at complex I (NADH-ubiquinone oxidoreductase). Unlike rotenone, MPP(+), annonaceous acetogenins, piericidin A, and other complex I inhibitors, mycothiazole is a mixed polyketide/peptide-derived compound …